• Explore /
  • Poster
  • / Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).

Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).

Abstract Poster

Authors

Anas Younes

Anas Younes

The University of Texas MD Anderson Cancer Center, Houston, TX

Anas Younes , John Radford , Stephen Maxted Ansell , Andrea Gallamini , Won Seog Kim , Tatyana A. Feldman , Mehdi Hamadani , Jeanenne Chung , Jingyuan Wang , Dirk Huebner , Joseph M. Connors

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Clinical Trial Registration Number

NCT01712490

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS8612)

DOI

10.1200/jco.2013.31.15_suppl.tps8612

Abstract #

TPS8612

Poster Bd #

57A

Abstract Disclosures

Similar Posters

First Author: Stephen Maxted Ansell

First Author: Howland E. Crosswell

First Author: Stephen M. Ansell

First Author: Christine Mauz-Körholz